Online first
Research paper
Published online: 2024-06-07

open access

Page views 49
Article views/downloads 26
Get Citation

Connect on Social Media

Connect on Social Media

Evaluating the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic and treatment response biomarkers in stage IV colorectal cancer patients

Abolghasem Allahyari1, Fahime Fallah1, Pegah Bahrami Taqanaki2, Seyyed Pouria Tafti2, Mohammad Moein Vakilzadeh2, Mohammad Moeini Nodeh1, Mostafa Kamandi1, Alireza Noferesti1

Abstract

Introduction. Stage IV colorectal cancer presents significant challenges in prognosis and treatment response. Reliable biomarkers are critical for predicting outcomes and guiding treatment choices. This study evaluated the efficacy of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as such biomarkers. 

Material and methods. Conducted at a hematology department in Mashhad, Iran, this study involved 105 patients diagnosed with stage IV colorectal cancer. Participants underwent complete blood count analysis before chemotherapy to determine the NLR and PLR. Clinical information was collected, including tumor size, location, and KRAS/NRAS/CEA levels. Post-treatment categorization followed the RECIST guidelines. 

Results. Median values for the NLR and PLR were 4.8 and 169.0, respectively. A higher NLR and PLR were significantly associated with progressive disease post-treatment. ROC analysis demonstrated the prognostic accuracy of the NLR (AUC 0.95) and PLR (AUC 0.90) at specific cutoffs. These markers also showed predictive accuracy for treatment response. Correlation analysis indicated a strong positive correlation between initial and post-treatment CEA levels and both the NLR and PLR. 

Conclusions. The NLR and PLR are significant predictors of clinical outcomes in stage IV colorectal cancer, with potential utility in routine clinical practice for prognosis and treatment response prediction. Their high sensitivity and specificity suggest a role in guiding clinical decision-making. Further research is needed to refine their application in CRC management.

Article available in PDF format

View PDF Download PDF file

References

  1. Sawicki T, Ruszkowska M, Danielewicz A, et al. A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. Cancers (Basel). 2021; 13(9).
  2. Feria A, Times M. Effectiveness of Standard Treatment for Stage 4 Colorectal Cancer: Traditional Management with Surgery, Radiation, and Chemotherapy. Clin Colon Rectal Surg. 2024; 37(2): 62–65.
  3. Koncina E, Haan S, Rauh S, et al. Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges. Cancers (Basel). 2020; 12(2).
  4. Lam M, Tie J, Lee B, et al. Systemic inflammation–impact on tumor biology and outcomes in colorectal cancer. J Clin Cell Immunol. 2015; 6(377): 2.
  5. Rossi S, Basso M, Strippoli A, et al. Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer? Clin Colorectal Cancer. 2017; 16(4): 264–274.
  6. Shibutani M, Maeda K, Nagahara H, et al. Significance of Markers of Systemic Inflammation for Predicting Survival and Chemotherapeutic Outcomes and Monitoring Tumor Progression in Patients with Unresectable Metastatic Colorectal Cancer. Anticancer Res. 2015; 35(9): 5037–5046.
  7. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228–247.
  8. Chan JCY, Diakos CI, Chan DLH, et al. A Longitudinal Investigation of Inflammatory Markers in Colorectal Cancer Patients Perioperatively Demonstrates Benefit in Serial Remeasurement. Ann Surg. 2018; 267(6): 1119–1125.
  9. Li Y, Jia H, Yu W, et al. Nomograms for predicting prognostic value of inflammatory biomarkers in colorectal cancer patients after radical resection. Int J Cancer. 2016; 139(1): 220–231.
  10. Jiang H, Li H, Li A, et al. Preoperative combined hemoglobin, albumin, lymphocyte and platelet levels predict survival in patients with locally advanced colorectal cancer. Oncotarget. 2016; 7(44): 72076–72083.
  11. Kim JH, Lee JY, Kim HK, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage III and IV colorectal cancer. World J Gastroenterol. 2017; 23(3): 505–515.
  12. Choi WJ, Cleghorn MC, Jiang H, et al. Preoperative Neutrophil-to-Lymphocyte Ratio is a Better Prognostic Serum Biomarker than Platelet-to-Lymphocyte Ratio in Patients Undergoing Resection for Nonmetastatic Colorectal Cancer. Ann Surg Oncol. 2015; 22 Suppl 3: S603–S613.
  13. Ying HQ, Deng QW, He BS, et al. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol. 2014; 31(12): 305.
  14. Pedrazzani C, Mantovani G, Fernandes E, et al. Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer. Sci Rep. 2017; 7(1): 1494.
  15. Ishizuka M, Nagata H, Takagi K, et al. Preoperative thrombocytosis is associated with survival after surgery for colorectal cancer. J Surg Oncol. 2012; 106(7): 887–891.
  16. Acikgoz O, Cakan B, Demir T, et al. Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer. Medicine (Baltimore). 2021; 100(44): e27712.
  17. Zou ZY, Liu HL, Ning N, et al. Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer. Oncol Lett. 2016; 11(3): 2241–2248.
  18. Jia W, Yuan L, Ni H, et al. Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy. Technol Cancer Res Treat. 2021; 20: 15330338211034291.
  19. Peng HX, Yang L, He BS, et al. Combination of preoperative NLR, PLR and CEA could increase the diagnostic efficacy for I-III stage CRC. J Clin Lab Anal. 2017; 31(5).
  20. Liu XF, Zhou LY, Wei ZH, et al. The diagnostic role of circulating inflammation-based biomarker in gallbladder carcinoma. Biomark Med. 2018; 12(10): 1095–1103.